We have developed and manufactured high-quality products as a comprehensive reagent manufacturer that can respond to the research needs of forefront fields with the fervently desire of "be helpful to all researchers" since establishment. Today, we have three core businesses domains, Laboratory Chemicals, Specialty Chemicals and Clinical Diagnostic reagents based on our advanced technology, and we are responding to the many needs from academia, companies and medical fields.
The Fujifilm Group has positioned two businesses as its growth drivers: the healthcare business, which addresses the three domains of prevention, diagnosis, and treatment; and the highly functional materials business, which handles materials and resources used in a range of industrial fields. We have been promoting business activities as the core group company handling healthcare and highly functional materials businesses of the Fujifilm Group through proactive business expansion overseas, in addition to applying the rigorous R&D, manufacturing, and sales base that has been built up in Japan over many years.
In January of this year, the Fujifilm Group celebrated its 90th anniversary, and on the occasion of this milestone, we discussed what role the Fujifilm Group should play in society to create a better future, and established the Group Purpose of "Giving our world more smiles”. With our new Group Purpose as our guide and aspiration, we will increase the number of smiles in the world.
As we look toward the next 100 years, we will not only develop new products and technologies that will become the next power of science, but also actively promote further globalization, strengthen our marketing capabilities, and streamline our operations, and as a company engaged in cutting-edge technology, we will continue to take on the challenge of increasing the number of smiles on the face of the earth. We will continue to take on the challenge as a company engaged in cutting-edge technology, and we hope to give our world more smiles.
Koichi Yoshida
President and CEO
April 2024